Aardvark Therapeutics AARD
NASDAQ AARD
$4.99 -0.28 (-5.31%)
At close: Oct 2, 2026 · 4:00 PM EDT

Aardvark Therapeutics (AARD) Return on Capital Employed [ROCE] (2025 - 2026)

Updated

Aardvark Therapeutics' Return on Capital Employed [ROCE] came in at -88.42% for Q2 2026, down 59.64 percentage points from -28.79% a year earlier and down 10.82 percentage points from the prior quarter.

Analysis

Aardvark Therapeutics (AARD) Return on Capital Employed [ROCE] (2025 - 2026) Analysis & Trends

For FY2025, Aardvark Therapeutics' Return on Capital Employed [ROCE] was -72.27%.

  • Business Quant data shows AARD's Return on Capital Employed [ROCE] at -77.60% (Q1 2026), -54.71% (Q4 2025) and -41.25% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 46.74%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 17.83%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 17.92%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 6.28%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 19.32%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 9.54%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 16.66%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -5.97%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 11.86%
10 Aardvark Therapeutics 109.20 Mn 35.30 Mn - -88.42%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -88.42%
Mar 31, 2026 -77.60%
Dec 31, 2025 -54.71%
Sep 30, 2025 -41.25%
Jun 30, 2025 -28.79%
Mar 31, 2025 -27.93%
API Access

Aardvark Therapeutics Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=AARD&period=max&api_key=YOUR_API_KEY